Sweden, Reason 1 O O
Denmark Reason 1 O O
pause Reason 1 O O
Moderna Reason 1 O O
COVID-19 Reason 1 O O
vaccine Reason 1 O O
for Reason 1 O O
younger Reason 1 O O
age Reason 1 O O
groups Reason 1 O O
STOCKHOLM, Reason 1 O O
Oct Reason 1 O O
6 Reason 1 O O
(Reuters) Reason 1 O O
- Reason 1 O O
Sweden Reason 1 O O
and Reason 1 O O
Denmark Reason 1 O O
said Reason 1 O O
on Reason 1 O O
Wednesday Reason 1 O O
they Reason 1 O O
are Reason 1 O O
pausing Reason 1 O O
the Reason 1 O O
use Reason 1 O O
of Reason 1 O O
Moderna's Reason 1 O O
[(MRNA.O)](https://www.reuters.com/companies/MRNA.O/) Reason 1 O O
COVID-19 Reason 1 O O
vaccine Reason 1 O O
for Reason 1 O O
younger Reason 1 O O
age Reason 1 O O
groups Reason 1 O O
after Reason 1 O O
reports Reason 1 O O
of Reason 1 O O
possible Reason 1 O O
rare Reason 1 O O
cardiovascular Reason 1 O O
side Reason 1 O O
effects. Reason 1 O O
The Reason 1 O O
Swedish Reason 1 O O
health Reason 1 O O
agency Reason 1 O O
said Reason 1 O O
it Reason 1 O O
would Reason 1 O O
pause Reason 1 O O
using Reason 1 O O
the Reason 1 O O
shot Reason 1 O O
for Reason 1 O O
people Reason 1 O O
born Reason 1 O O
in Reason 1 O O
1991 Reason 1 O O
and Reason 1 O O
later Reason 1 O O
as Reason 1 O O
data Reason 1 O O
pointed Reason 1 O O
to Reason 1 O O
an Reason 1 O O
increase Reason 1 O O
of Reason 1 O O
myocarditis Reason 1 O O
and Reason 1 O O
pericarditis Reason 1 O O
among Reason 1 O O
youths Reason 1 O O
and Reason 1 O O
young Reason 1 O O
adults Reason 1 O O
that Reason 1 O O
had Reason 1 O O
been Reason 1 O O
vaccinated. Reason 1 O O
Those O O O O
conditions O O O O
involve O O O O
an O O O O
inflammation O O O O
of O O O O
the O O O O
heart O O O O
or O O O O
its O O O O
lining. O O O O
"The Reason 1 O O
connection Reason 1 O O
is Reason 1 O O
especially Reason 1 O O
clear Reason 1 O O
when Reason 1 O O
it Reason 1 O O
comes Reason 1 O O
to Reason 1 O O
Moderna's Reason 1 O O
vaccine Reason 1 O O
Spikevax, Reason 1 O O
especially Reason 1 O O
after Reason 1 O O
the Reason 1 O O
second Reason 1 O O
dose," Reason 1 O O
the Reason 1 O O
health Reason 1 O O
agency Reason 1 O O
said, Reason 1 O O
adding Reason 1 O O
the Reason 1 O O
risk Reason 1 O O
of Reason 1 O O
being Reason 1 O O
affected Reason 1 O O
was Reason 1 O O
very Reason 1 O O
small. Reason 1 O O
Shares O O O O
of O O O O
Moderna O O O O
fell O O O O
4.9%, O O O O
or O O O O
$16.08, O O O O
to O O O O
$316.11 O O O O
in O O O O
afternoon O O O O
trading. O O O O
A Reason 2 O O
Moderna Reason 2 O O
spokesperson Reason 2 O O
said Reason 2 O O
in Reason 2 O O
an Reason 2 O O
email Reason 2 O O
the Reason 2 O O
company Reason 2 O O
was Reason 2 O O
aware Reason 2 O O
of Reason 2 O O
the Reason 2 O O
decisions Reason 2 O O
by Reason 2 O O
regulators Reason 2 O O
in Reason 2 O O
Denmark Reason 2 O O
and Reason 2 O O
Sweden Reason 2 O O
to Reason 2 O O
pause Reason 2 O O
the Reason 2 O O
use Reason 2 O O
of Reason 2 O O
its Reason 2 O O
vaccine Reason 2 O O
in Reason 2 O O
younger Reason 2 O O
individuals Reason 2 O O
because Reason 2 O O
of Reason 2 O O
the Reason 2 O O
rare Reason 2 O O
risk Reason 2 O O
of Reason 2 O O
myocarditis Reason 2 O O
and Reason 2 O O
or Reason 2 O O
pericarditis. Reason 2 O O
"These Reason 4 O O
are Reason 4 O O
typically Reason 4 O O
mild Reason 4 O O
cases Reason 4 O O
and Reason 4 O O
individuals Reason 4 O O
tend Reason 4 O O
to Reason 4 O O
recover Reason 4 O O
within Reason 4 O O
a Reason 4 O O
short Reason 4 O O
time Reason 4 O O
following Reason 4 O O
standard Reason 4 O O
treatment Reason 4 O O
and Reason 4 O O
rest. Reason 4 O O
The Reason 5 O O
risk Reason 5 O O
of Reason 5 O O
myocarditis Reason 5 O O
is Reason 5 O O
substantially Reason 5 O O
increased Reason 5 O O
for Reason 5 O O
those Reason 5 O O
who Reason 5 O O
contract Reason 5 O O
COVID-19, Reason 5 O O
and Reason 5 O O
vaccination Reason 5 O O
is Reason 5 O O
the Reason 5 O O
best Reason 5 O O
way Reason 5 O O
to Reason 5 O O
protect Reason 5 O O
against Reason 5 O O
this." Reason 5 O O
According Reason 5 O O
to Reason 5 O O
one Reason 5 O O
U.S. Reason 5 O O
study Reason 5 O O
that Reason 5 O O
has Reason 5 O O
yet Reason 5 O O
to Reason 5 O O
undergo Reason 5 O O
peer Reason 5 O O
review Reason 5 O O
young Reason 5 O O
males Reason 5 O O
under Reason 5 O O
20 Reason 5 O O
are Reason 5 O O
up Reason 5 O O
to Reason 5 O O
six Reason 5 O O
times Reason 5 O O
more Reason 5 O O
likely Reason 5 O O
to Reason 5 O O
develop Reason 5 O O
myocarditis Reason 5 O O
after Reason 5 O O
contracting Reason 5 O O
COVID-19 Reason 5 O O
than Reason 5 O O
those Reason 5 O O
who Reason 5 O O
have Reason 5 O O
been Reason 5 O O
vaccinated. Reason 5 O O
Denmark Reason 2 O O
said Reason 2 O O
that, Reason 2 O O
while Reason 2 O O
it Reason 2 O O
used Reason 2 O O
the Reason 2 O O
Pfizer/BioNTech Reason 2 O O
vaccine Reason 2 O O
as Reason 2 O O
its Reason 2 O O
main Reason 2 O O
option Reason 2 O O
for Reason 2 O O
people Reason 2 O O
aged Reason 2 O O
12-17 Reason 2 O O
years, Reason 2 O O
it Reason 2 O O
had Reason 2 O O
decided Reason 2 O O
to Reason 2 O O
pause Reason 2 O O
giving Reason 2 O O
the Reason 2 O O
Moderna Reason 2 O O
vaccine Reason 2 O O
to Reason 2 O O
people Reason 2 O O
below Reason 2 O O
18 Reason 2 O O
according Reason 2 O O
to Reason 2 O O
a Reason 2 O O
"precautionary Reason 2 O O
principle". Reason 2 O O
"In Reason 2 O O
the Reason 2 O O
preliminary Reason 2 O O
data Reason 2 O O
... Reason 2 O O
there Reason 2 O O
is Reason 2 O O
a Reason 2 O O
suspicion Reason 2 O O
of Reason 2 O O
an Reason 2 O O
increased Reason 2 O O
risk Reason 2 O O
of Reason 2 O O
heart Reason 2 O O
inflammation, Reason 2 O O
when Reason 2 O O
vaccinated Reason 2 O O
with Reason 2 O O
Moderna," Reason 2 O O
the Reason 2 O O
Danish Reason 2 O O
Health Reason 2 O O
Authority Reason 2 O O
said Reason 2 O O
in Reason 2 O O
a Reason 2 O O
statement. Reason 2 O O
It O O O O
referred O O O O
to O O O O
data O O O O
from O O O O
a O O O O
yet O O O O
unpublished O O O O
Nordic O O O O
study, O O O O
which O O O O
would O O O O
now O O O O
be O O O O
sent O O O O
to O O O O
the O O O O
European O O O O
Medicines O O O O
Agency O O O O
(EMA) O O O O
for O O O O
further O O O O
assessment. O O O O
Final O O O O
data O O O O
was O O O O
expected O O O O
within O O O O
a O O O O
month, O O O O
it O O O O
added. O O O O
Sweden Reason 4 O O
and Reason 4 O O
Denmark Reason 4 O O
said Reason 4 O O
they Reason 4 O O
now Reason 4 O O
recommended Reason 4 O O
the Reason 4 O O
Comirnaty Reason 4 O O
vaccine, Reason 4 O O
from Reason 4 O O
Pfizer/BioNTech Reason 4 O O
[(PFE.N)](https://www.reuters.com/companies/PFE.N/), Reason 4 O O
instead. Reason 4 O O
The O O O O
Danish O O ScientificAuthority O
Health O O ScientificAuthority O
Authority O O ScientificAuthority O
said O O O O
it O O O O
had O O O O
made O O O O
the O O O O
decision O O O O
even O O O O
as O O O O
"heart O O O O
inflammation O O O O
is O O O O
an O O O O
extremely O O O O
rare O O O O
side O O O O
effect O O O O
that O O O O
often O O O O
has O O O O
a O O O O
mild O O O O
course O O O O
and O O O O
goes O O O O
away O O O O
on O O O O
its O O O O
own". O O O O
The Reason 1 O O
EMA's Reason 1 O O
safety Reason 1 O O
committee Reason 1 O O
concluded Reason 1 O O
in Reason 1 O O
July Reason 1 O O
that Reason 1 O O
inflammatory Reason 1 O O
heart Reason 1 O O
conditions Reason 1 O O
can Reason 1 O O
occur Reason 1 O O
[in Reason 1 O O
very Reason 1 O O
rare Reason 1 O O
cases](https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-lists-heart-condition-possible-side-effect-mrna-vaccines-2021-07-09/) Reason 1 O O
following Reason 1 O O
vaccination Reason 1 O O
with Reason 1 O O
Comirnaty Reason 1 O O
or Reason 1 O O
Spikevax, Reason 1 O O
more Reason 1 O O
often Reason 1 O O
in Reason 1 O O
younger Reason 1 O O
men Reason 1 O O
after Reason 1 O O
the Reason 1 O O
second Reason 1 O O
dose. Reason 1 O O
The O O O O
benefits O O O O
of O O O O
shots O O O O
based O O O O
on O O O O
so-called O O O O
mRNA O O O O
technology O O O O
used O O O O
by O O O O
both O O O O
Moderna O O O O
and O O O O
Pfizer-BioNTech O O O O
in O O O O
preventing O O O O
COVID-19 O O O O
continue O O O O
to O O O O
outweigh O O O O
the O O O O
risks, O O O O
regulators O O O O
in O O O O
the O O O O
United O O O O
States, O O O O
EU O O O O
and O O O O
the O O O O
World O O ScientificAuthority O
Health O O ScientificAuthority O
Organization O O ScientificAuthority O
have O O O O
said. O O O O
Data O O O O
suggests O O O O
reported O O O O
cases O O O O
of O O O O
rare O O O O
heart O O O O
inflammation O O O O
are O O O O
relatively O O O O
higher O O O O
[after O O O O
Moderna's O O O O
vaccine](https://www.reuters.com/business/healthcare-pharmaceuticals/heart-inflammation-rates-higher-after-moderna-covid-19-shot-than-pfizer-vaccine-2021-10-01/) O O O O
compared O O O O
with O O O O
the O O O O
Pfizer/BioNTech O O O O
shots, O O O O
Canadian O O O O
health O O O O
officials O O O O
said O O O O
last O O O O
week. O O O O
Although O O O O
both O O O O
vaccines O O O O
are O O O O
based O O O O
on O O O O
mRNA O O O O
technology, O O O O
the O O O O
Pfizer O O O O
shot O O O O
contains O O O O
30 O O O O
micrograms O O O O
of O O O O
vaccine O O O O
per O O O O
dose O O O O
compared O O O O
with O O O O
100 O O O O
micrograms O O O O
in O O O O
the O O O O
Moderna O O O O
vaccine. O O O O
Data Reason 1 O O
from Reason 1 O O
one Reason 1 O O
of Reason 1 O O
two Reason 1 O O
U.S. Reason 1 O O
vaccine Reason 1 O O
safety Reason 1 O O
monitoring Reason 1 O O
databases Reason 1 O O
has Reason 1 O O
also Reason 1 O O
suggested Reason 1 O O
that Reason 1 O O
Moderna's Reason 1 O O
vaccine Reason 1 O O
may Reason 1 O O
carry Reason 1 O O
a Reason 1 O O
higher Reason 1 O O
risk Reason 1 O O
of Reason 1 O O
myocarditis Reason 1 O O
among Reason 1 O O
young Reason 1 O O
people. Reason 1 O O
The Reason 1 O O
vaccine Reason 1 O O
is Reason 1 O O
not Reason 1 O O
approved Reason 1 O O
for Reason 1 O O
people Reason 1 O O
under Reason 1 O O
age Reason 1 O O
18 Reason 1 O O
in Reason 1 O O
the Reason 1 O O
United Reason 1 O O
States. Reason 1 O O
Norway O O O O
already O O O O
recommends O O O O
the O O O O
Cominarty O O O O
vaccine O O O O
to O O O O
minors O O O O
and O O O O
said O O O O
on O O O O
Wednesday O O O O
that O O O O
it O O O O
was O O O O
reiterating O O O O
this. O O O O
"Men O O O O
under O O O O
the O O O O
age O O O O
of O O O O
30 O O O O
should O O O O
also O O O O
consider O O O O
choosing O O O O
Cominarty O O O O
when O O O O
they O O O O
get O O O O
vaccinated," O O O O
Geir O O O O
Bukholm, O O O O
head O O O O
of O O O O
infection O O O O
control O O O O
at O O O O
the O O O O
Norwegian O O ScientificAuthority O
Institute O O ScientificAuthority O
of O O ScientificAuthority O
Public O O ScientificAuthority O
Health, O O ScientificAuthority O
said O O O O
in O O O O
a O O O O
statement. O O O O
A O O O O
Finnish O O O O
health O O O O
official O O O O
said O O O O
Finland O O O O
expected O O O O
to O O O O
publish O O O O
a O O O O
decision O O O O
on O O O O
Thursday. O O O O
The O O O O
EMA O O O O
approved O O O O
the O O O O
use O O O O
of O O O O
[Comirnaty O O O O
in O O O O
May](https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-endorses-pfizer-biontech-covid-19-vaccine-adolescents-2021-05-28/), O O O O
while O O O O
Spikevax O O O O
was O O O O
given O O O O
the O O O O
nod O O O O
for O O O O
children O O O O
over O O O O
12 O O O O
in O O O O
July. O O O O
Reporting O O O O
by O O O O
Johan O O O O
Ahlander O O O O
in O O O O
Stockholm O O O O
and O O O O
Stine O O O O
Jacobsen O O O O
in O O O O
Copenhagen; O O O O
Additional O O O O
reporting O O O O
by O O O O
Gwladys O O O O
Fouche O O O O
in O O O O
Oslo, O O O O
Julie O O O O
Steenhuysen O O O O
in O O O O
Chicago, O O O O
Michael O O O O
Erman O O O O
in O O O O
New O O O O
York; O O O O
Editing O O O O
by O O O O
Kirsten O O O O
Donovan, O O O O
Alex O O O O
Richardson O O O O
and O O O O
Alison O O O O
Williams O O O O
Our O O O O
Standards: O O O O
